4-Chlorosulfonyl-5-methylsulfanyl-thiophene-2-carboxylic acid methyl ester | 631909-59-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 4-Chlorosulfonyl-5-methylsulfanyl-thiophene-2-carboxylic acid methyl ester
• 英文别名: Methyl 4-chlorosulfonyl-5-methylsulfanylthiophene-2-carboxylate；methyl 4-chlorosulfonyl-5-methylsulfanylthiophene-2-carboxylate
• CAS: 631909-59-6
• 化学式: C₇H₇ClO₄S₃
• 分子量: 286.781
• InChiKey: JNOQLBLXMUGZDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  122
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-Chlorosulfonyl-5-methylsulfanyl-thiophene-2-carboxylic acid methyl ester 在 sodium dithionite 、 碳酸氢钠 、 溶剂黄146 、 sodium sulfite 作用下， 以 乙醇 为溶剂， 生成 4-(7-Chloro-1H-benzoimidazole-5-sulfonyl)-5-methylsulfanyl-thiophene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s

  摘要：

  Inhibiting the classical pathway of complement activation by attenuating the proteolytic activity of the serine protease C1s is a potential strategy for the therapeutic intervention in disease states such as hereditary angioedema, ischemia-reperfusion injury, and acute transplant rejection. A series of arylsulfonylthiophene-2-carboximidine inhibitors of C1s were synthesized and evaluated for C1s inhibitory activity. The most potent compound had a K-i of 10 nM and >1000-fold selectivity over uPA, tPA, FXa, thrombin, and plasmin. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.036
• 作为产物：
  描述：

  甲基4-氨基-5-(甲硫基)-2-噻吩羧酸酯 在 盐酸 、 亚硝酸特丁酯 、 二氧化硫 、 copper dichloride 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 2.0h， 以35%的产率得到4-Chlorosulfonyl-5-methylsulfanyl-thiophene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS
  [FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT

  摘要：

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。

  公开号：

  WO2003099805A1

文献信息

• [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS<br/>[FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2003099805A1

  公开（公告）日：2003-12-04

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。
• Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040009995A1

  公开（公告）日：2004-01-15

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 and R 7 are defined in the specification, Z is SO or SO 2 , and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。
• NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS
  申请人：3-DIMENSIONAL PHARMACEUTICALS, INC.

  公开号：EP1549632A1

  公开（公告）日：2005-07-06
• EP1549632A4
  申请人：——

  公开号：EP1549632A4

  公开（公告）日：2005-11-09
• US7138530B2
  申请人：——

  公开号：US7138530B2

  公开（公告）日：2006-11-21